ProfileGDS5678 / 1455283_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 96% 96% 95% 96% 96% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.7124696
GSM967853U87-EV human glioblastoma xenograft - Control 29.0299296
GSM967854U87-EV human glioblastoma xenograft - Control 39.0970596
GSM967855U87-EV human glioblastoma xenograft - Control 48.99396
GSM967856U87-EV human glioblastoma xenograft - Control 58.9383796
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.4589396
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.324995
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.8218896
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.9261896
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.762396
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6148296
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.8722896
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.8115296
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.8670596